Last updated: February 15, 2026
What Is the Current Market Status for NDC 00904-7472?
NDC 00904-7472 refers to Remdesivir (Veklury), marketed by Gilead Sciences. Approved by the FDA in October 2020 for COVID-19 treatment, Remdesivir remains in demand as an antiviral for hospitalized COVID-19 patients. Its market position has shifted with the emergence of new treatments and evolving guidelines, but it retains a significant share in its therapeutic niche.
How Does the Market for Remdesivir (NDC 00904-7472) Compare to Similar Antivirals?
| Parameter |
Remdesivir (Veklury) |
Molnupiravir (Lagevrio) |
Paxlovid (Pfizer) |
| FDA Approval Date |
October 2020 |
December 2021 |
December 2021 |
| Indications |
COVID-19 hospitalized, early treatment |
Mild to moderate COVID-19, outpatient |
Mild to moderate COVID-19, outpatient |
| Administration Route |
Intravenous (IV) |
Oral |
Oral |
| Price (per treatment course) |
~$2,340 (hospital reimbursement rate, US) |
~$700 |
~$530 |
| Peak Market Share (2022) |
Estimated 20-25% of COVID-19 outpatient market |
Not significant; early market phase |
Dominates outpatient COVID-19 market |
Market share data indicate remdesivir's primary use in hospitals, with outpatient antiviral treatments increasingly overshadowing it. As of 2022, it accounts for a smaller share of COVID-19 therapies overall, with competition from oral agents.
What Are the Price Projections for Remdesivir?
Short-Term (Next 12 Months)
- Price Trend: The U.S. payment rate remains stable around $2,340 per course, reflecting hospital reimbursement policies.
- Market Forces: The introduction of oral antivirals, regulatory guidance favoring outpatient treatments, and national stockpile adjustments could reduce demand.
- Pricing pressure: Manufacturers may face pressure to lower prices amid competitive therapies, especially as generic insinuations surface in other jurisdictions.
Long-Term (Next 3-5 Years)
- Market contraction: Likely decline as COVID-19 transitions from pandemic to endemic, reducing hospitalization rates.
- Potential demand: Stable for stockpiling and hospital use, especially in regions lacking robust outpatient alternatives.
- Price floor: Estimated at approximately 50% of current levels in U.S. markets without policy interventions, especially in low-resource settings.
Factors Influencing Pricing and Market Dynamics
- Regulatory decisions: Approval extension or withdrawal influences market volume.
- Patent status: Patent expiry or patent challenges in foreign markets could introduce generics, lowering prices substantially.
- Reimbursement policies: Shifts in hospital and government reimbursements directly impact revenue.
What Are the Key Market Risks and Opportunities?
Risks
- Market saturation: Decline in COVID-19 hospitalization rates reduces demand.
- Competitive therapies: Oral treatments rapidly gain market share due to ease of administration.
- Regulatory changes: Authorities may restrict or expand indications affecting demand.
Opportunities
- New indications: Investigations into remdesivir for other viral infections could expand use.
- Global demand: Growing needs in low- and middle-income countries, where oral antivirals are less accessible.
- Combination therapies: Potential for remdesivir in combination treatments could extend relevance.
What Are the Main Drivers of Future Revenue for NDC 00904-7472?
- Endemic COVID-19 management: Continued use in hospitals.
- Supplies for outbreak preparedness: Stockpiling in vulnerable nations.
- New clinical research: Demonstration of broader antiviral efficacy.
Summary of Data Points and Policy Considerations
- Market Size (2022): Estimated at $1.15 billion globally, with U.S. sales accounting for over half.
- Price Trend (2023-2027): Predicted to fall 30-50%, driven by market competition.
- Regulatory outlook: FDA re-evaluation of COVID-19 treatment protocols anticipated by mid-2024.
Key Takeaways
- Remdesivir's market is in decline, with shifting treatment preferences favoring oral antivirals.
- Price projections indicate a significant reduction within the next five years, especially outside the U.S.
- Risks include decreased demand as COVID-19 becomes endemic; opportunities exist in global health markets.
- Competitive landscape evolves rapidly, influencing market share and pricing.
- Policy changes and clinical research outcomes will shape the long-term outlook.
FAQs
1. Will remdesivir keep its market share in hospital settings?
In the short term, yes. Hospital settings rely on IV antivirals for severe cases, maintaining remdesivir's role. Long-term, its share declines as outpatient oral therapies grow.
2. How will patent expirations affect remdesivir pricing?
Patent expirations, likely in developing countries by 2025, could lead to generic entry, substantially reducing prices in those markets.
3. Are there new FDA approvals planned for remdesivir?
No current public plans exist for additional indications beyond COVID-19. However, ongoing research seeks broader antiviral applications.
4. How does remdesivir compare to oral antivirals in terms of cost-effectiveness?
Oral agents like paxlovid are lower cost ($530 per course) and easier to administer, making them more attractive in outpatient settings.
5. Can remdesivir gain a foothold in treatments for other viral infections?
Potential exists if clinical trials demonstrate efficacy, but no such developments are currently underway.
Sources:
[1] U.S. Food and Drug Administration. "Veklury (remdesivir) Prescribing Information," 2020.
[2] IQVIA. "COVID-19 Antiviral Market Trends," 2022.
[3] Gilead Sciences. "Veklury Pricing and Market Data," 2022.
[4] Statista. "Global COVID-19 Treatment Market," 2022.
